Skint Records

PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors

Retrieved on: 
Thursday, September 8, 2022
COVID-19, BLA, IND, Regulation of tobacco by the U.S. Food and Drug Administration, Doctor of Philosophy, Risk, SALT, Board, Food, SEC, Intention, Leadership, Board of directors, Biotechnology, Company, Report, FDA, PTE, Clinical trial, Skint Records, Private Securities Litigation Reform Act, Pharmaceutical industry

"On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE.

Key Points: 
  • "On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE.
  • Dr. Dyer stated, "It has been an honor to serve as a director of PolarityTE.
  • Dr. Dyer went on to say, "I want to thank my fellow directors and wish the Company nothing but success."
  • POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are registered trademarks of PolarityTE, Inc.

PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

Retrieved on: 
Monday, August 1, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, SALT, Food, Skint Records, Financial result, NASDAQ, Webcast, Q&A, Biotechnology, FDA, Company, PTE, IND, Pharmaceutical industry

SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ --PolarityTE, Inc. (NASDAQ: PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time.

Key Points: 
  • SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ --PolarityTE, Inc. (NASDAQ: PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time.
  • In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time.
  • The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results."
  • POLARITYTE, the POLARITYTE logo, SKINTE, and WHERE SELF REGENERATES SELF are registered trademarks of PolarityTE, Inc.

Lifshitz Law PLLC Announces Investigations of Cassava Sciences, Inc. (NASDAQCM: SAVA), The Honest Company, Inc. (NASDAQGS: HNST), PolarityTE, Inc. (NASDAQCM: PTE), Selectquote, Inc. (NYSE: SLQT) SAVA, HNST, PTE, and SLQT

Retrieved on: 
Wednesday, May 11, 2022
Hewlett, Telephone, Company, Diaper, Wellness, Advertising, Registration statement, COVID-19, Control, FDA, Register, IND, Lists of schools in England, PTE, Cassava, IPO, Skint Records, Household, Pharmaceutical industry, Online shopping, Chemistry

If you are a Cassava investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are a Cassava investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • If you are an HNST investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.
  • Prior results do not guarantee or predict a similar outcome with respect to any future matter.

PolarityTE to Report Q1 2021 Financial Results on May 16, 2022

Retrieved on: 
Friday, May 6, 2022
IND, PTE, Q&A, Skint Records, SALT, Company, Biotechnology, Food, BLA, Webcast, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

SALT LAKE CITY, May 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May 16, 2022, at approximately 7:30 a.m. Eastern Time.

Key Points: 
  • SALT LAKE CITY, May 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May 16, 2022, at approximately 7:30 a.m. Eastern Time.
  • In addition, the Company will host a conference call and webcast with Q&A on May 16, 2022, at 8:30 a.m. Eastern Time.
  • The conference call can be accessed by calling 1-800-289-0459 with passcode 399675 and referencing "PolarityTE First Quarter 2022 Business Update".
  • POLARITYTE, the POLARITYTE logo, SKINTE, and WHERE SELF REGENERATES SELF are registered trademarks of PolarityTE, Inc.

PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 30, 2022
BLA, IBEX, Company, Private Securities Litigation Reform Act, Exercise, Richard Wagner, VLU, Mission statement, PTE, Marketing, Risk, Clinical trial, Growth, Comparison, Skin, Mouth ulcer, Burns, Biotechnology, SEC, CMC, Research, SOC, DFU, Paycheck Protection Program, PAR, Food, Consolidated, SALT, Operating cost, COVID-19 testing, Element, Calendar, Intention, Period, Earnings call, International, Report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Randomized controlled trial, Judgement, Liquidity, Consultant, COVID, FDA, Patient, Video game, Online gambling, Pharmaceutical industry, Medical imaging, Silviculture, Security (finance), Animal, Cryptocurrency, Online shopping, Polarity, IND, Skint Records

SALT LAKE CITY, March 30, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the twelve-month period ended December 31, 2021.

Key Points: 
  • ET
    SALT LAKE CITY, March 30, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the twelve-month period ended December 31, 2021.
  • Financial Results for the Period Ended December 31, 2021
    PolarityTE is a clinical stage biotechnology company developing regenerative tissue products and biomaterials.
  • As a result of these developments net revenues from services remained essentially unchanged in fiscal year 2021 compared to fiscal year 2020.
  • POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are registered trademarks of PolarityTE, Inc.

PolarityTE to Report Fiscal Year 2021 Financial Results on March 30, 2022

Retrieved on: 
Thursday, March 10, 2022
International, BLA, PTE, Earnings call, SALT, Company, IND, Webcast, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Q&A, Skint Records, Food, Biotechnology, Pharmaceutical industry

SALT LAKE CITY, March 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30, 2022, at approximately 7:30 a.m. Eastern Time.

Key Points: 
  • SALT LAKE CITY, March 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30, 2022, at approximately 7:30 a.m. Eastern Time.
  • In addition, the Company will host a conference call and webcast with Q&A on March 30, 2022, at 8:30 a.m. Eastern Time.
  • The conference call can be accessed by calling 1-800-581-5838 (U.S. and Canada) or +44 (0)330 165 3641 (International) with confirmation code 361897 and referencing "PolarityTE Fiscal Year 2021 Earnings Call".
  • POLARITYTE, the POLARITYTE logo, SKINTE, and WHERE SELF REGENERATES SELF are registered trademarks of PolarityTE, Inc.

PolarityTE Announces Allowance of Fourth U.S. Patent

Retrieved on: 
Thursday, February 17, 2022
Intellectual property, Food, USPTO, Company, SEC, Private Securities Litigation Reform Act, IND, Report, Regulation of tobacco by the U.S. Food and Drug Administration, Risk, Technology, Intention, Patent, Biotechnology, FDA, PTE, SALT, BLA, COVID-19, Pharmaceutical industry, Skint Records

This is the Company's fourth patent allowance in the United States.

Key Points: 
  • This is the Company's fourth patent allowance in the United States.
  • Mary Bram, Vice President of Intellectual Property, commented: "This allowance is a significant step forward in building out the Company's patent portfolio in the United States.
  • Richard Hague, Chief Executive Officer and President of PolarityTE, commented: "PolarityTE understands the importance of intellectual property and building a patent portfolio that protects our regenerative tissue technology embodied in SkinTE.
  • POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are registered trademarks of PolarityTE, Inc.

PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

Retrieved on: 
Tuesday, January 18, 2022
Shift, Skint Records, PTE, Medicine, Patient, PAR, Intention, VLU, Report, Mortality, Biotechnology, Incidence, Private Securities Litigation Reform Act, SEC, BLA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Randomized controlled trial, COVID-19, Growth, Risk, IND, Tissue, Biomedical engineering, Company, Quality of life, SALT, Cancer, Food, Infection, FDA, DFU, Pharmaceutical industry

SALT LAKE CITY, Jan. 18, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for the evaluation of SkinTE for the treatment of chronic cutaneous ulcers. This follows the Company satisfactorily addressing clinical hold items that the FDA had previously identified.  The approval enables PolarityTE to commence the first of two expected pivotal studies needed to support a biologics license application (BLA) seeking a chronic cutaneous ulcer indication for SkinTE. 

Key Points: 
  • The approval enables PolarityTE to commence the first of two expected pivotal studies needed to support a biologics license application (BLA) seeking a chronic cutaneous ulcer indication for SkinTE.
  • The first planned pivotal study is a multi-center, randomized controlled trial evaluating SkinTE in the treatment of Wager 2 DFUs entitled "Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE," or "COVER DFUs."
  • PolarityTE's products, including SkinTE, are in the development stage, and when clinical studies commence, SkinTE will be available for investigational use only.
  • POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are registered trademarks of PolarityTE, Inc.

Lifshitz Law Firm, P.C. Announces Investigations of AppHarvest, Inc. (NASDAQGS: APPH), The Boston Beer Company, Inc. (NYSE: SAM), The Honest Company, Inc. (NASDAQGS: HNST), and PolarityTE, Inc. (NASDAQCM: PTE)

Retrieved on: 
Thursday, December 23, 2021
Register, Wellness, Hewlett, Diaper, Registration statement, Control, APPH, Telephone, IND, Advertising, PTE, IPO, COVID-19, Skint Records, Defendant, Household, Company, Law firm, P.C, FDA, SAM, Pharmaceutical industry, Online shopping, Private investigator, Chemistry

If you are an APPH investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are an APPH investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • If you are a SAM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • The law firm responsible for this advertisement is Lifshitz Law Firm, P.C., 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.
  • Prior results do not guarantee or predict a similar outcome with respect to any future matter.

POLARITYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating PolarityTE, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, December 2, 2021
Legal, Professional Services, FDA, P.C, Lists of schools in England, Control, IND, PTE, Advertising, NASDAQ, Telephone, Company, Skint Records, Jeanne Eagels (film), Pharmaceutical industry

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PolarityTE, Inc. (NASDAQ: PTE) on behalf of long-term stockholders following a class action complaint that was filed against PolarityTE on September 24, 2021.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PolarityTE, Inc. (NASDAQ: PTE) on behalf of long-term stockholders following a class action complaint that was filed against PolarityTE on September 24, 2021.
  • Our investigation concerns whether the board of directors of PolarityTE have breached their fiduciary duties to the company.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operational and compliance policies.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.